Phase I study of topotecan in combination with concurrent radiotherapy in adults with glioblastoma

Journal of Neuro-Oncology

Volumn 65, Issue 2, 2003, Pages 141-148

  Lesimple, Thierry ^a   Hassel, Mohammed B ^b   Gédouin, Daniel ^a   Seigneuret, Eric ^c   Carsin, Béatrice ^d   Hamlat, Abderrahmane ^c   Riffaud, Laurent ^c   Simon, Hélène ^e   Malhaire, Jean P ^f   Guégan, Yvon ^c  

^a Medical Oncology Unit   (France)

^b Radiotherapy Unit   (France)

^c Neurosurgery Unit   (France)

^d Radiology Unit   (France)

^e Medical Oncology Unit   (France)

^f Radiotherapy Unit   (France)

Author keywords

Glioblastoma; Phase I trial; Radiotherapy; Topotecan

Indexed keywords

ANTICONVULSIVE AGENT; ANTINEOPLASTIC AGENT; CORTICOSTEROID; NITROSOUREA DERIVATIVE; TEMOZOLOMIDE; TOPOTECAN; VALPROIC ACID;

ADULT; AGED; ANEMIA; ARTICLE; ASTHENIA; BLOOD TOXICITY; BRAIN SURGERY; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; CONFUSION; CONJUNCTIVITIS; CONTINUOUS INFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE CALCULATION; DRUG FEVER; ERYTHEMA; FEBRILE NEUTROPENIA; FEMALE; GLIOBLASTOMA; HEADACHE; HISTOPATHOLOGY; HUMAN; INFECTION; INSOMNIA; LEUKOPENIA; MALE; MAXIMUM TOLERATED DOSE; NEUROLOGIC DISEASE; NEUTROPENIA; PHASE 1 CLINICAL TRIAL; POSTOPERATIVE CARE; RADIATION DOSE FRACTIONATION; RHABDOID TUMOR; SEIZURE; SIDE EFFECT; SKIN TOXICITY; SKULL IRRADIATION; STEREOTAXIC SURGERY; THROMBOCYTE TRANSFUSION; THROMBOCYTOPENIA; TUMOR BIOPSY; VOMITING; WEIGHT REDUCTION;

ADOLESCENT; ADULT; AGED; ANTINEOPLASTIC AGENTS; BRAIN NEOPLASMS; COMBINED MODALITY THERAPY; CRANIAL IRRADIATION; FEMALE; GLIOBLASTOMA; HUMANS; INFUSION PUMPS; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; SURVIVAL RATE; TOPOTECAN;

EID: 10744224268     PISSN: 0167594X     EISSN: None     Source Type: Journal    
DOI: 10.1023/B:NEON.0000003647.66788.3b     Document Type: Article

References (37)

1. Walker MD, Green SB, Byar DP, Alexander E Jr, Batzdorf U, Brooks WH, Hunt WE, MacCarty CS, Mahaley MS Jr, Mealey J Jr, Owens G, Ransohoff J 2nd, Robertson JT, Shapiro WR, Smith KR Jr, Wilson CB, Strike TA: Randomized comparisons of radiotherapy and nitrosoureas for the treatment of malignant glioma after surgery. N Engl J Med 303: 1323-1329, 1980
2. Sandberg-Wollheim M, Malmstrom P, Stromblad LG, Anderson H, Borgstrom S, Brun A, Cronqvist S, Hougaard K, Salford LG: A randomized study of chemotherapy with procarbazine, vincristine, and lomustine with and without radiation therapy for astrocytoma grades 3 and/or 4. Cancer 68: 22-29, 1991
3. Surawicz TS, Davis F, Freels S, Laws ER Jr, Menck HR: Brain tumor survival: Results from the National Cancer Data Base. J Neuro-Oncol 40: 151-160, 1998
4. Kreth FW, Berlis A, Spiropoulou V, Faist M, Scheremet R, Rossner R, Volk B, Ostertag CB: The role of tumor resection in the treatment of glioblastoma multiforme in adults. Cancer 86: 2117-2123, 1999
5. Fine HA, Dear KB, Loeffler JS, Black PM, Canellos GP: Meta-analysis of radiation therapy with and without adjuvant chemotherapy for malignant gliomas in adults. Cancer 71: 2585-2597, 1993
6. Thomas DGT, Bleehen JT, Roberts JT, Abram P, Brada M, Lantos PL, Moss TH, Ironside JW, Whaley JB, Stenning SP for the MRC Brain Tumour Working Party: MRC randomized trial of adjuvant chemotherapy in high grade glioma (HGG) - BR05. J Neuro-Oncol 101, 1998 (Abstract)
7. Friedman HS, Houghton PJ, Schold SC, Keir S, Bigner DD: Activity of 9-dimethylaminomethyl-10-hydroxycamptothecin against pediatric and adult central nervous system tumor xenografts. Cancer Chemother Pharmacol 34: 171-174, 1994
8. Blaney SM, Phillips PC, Packer RJ, Heideman RL, Berg SL, Adamson PC, Allen JC, Sallan SE, Jakacki RI, Lange BJ, Reaman GH, Horowitz ME, Poplack DG, Balis FM: Phase II evaluation of topotecan for pediatric central nervous system tumors. Cancer 78: 527-531, 1996
9. Macdonald D, Cairncross G, Stewart D, Forsyth P, Sawka C, Wainman N, Eisenhauer E: Phase II study of topotecan in patients with recurrent malignant glioma. National Clinical Institute of Canada Clinical Trials Group. Ann Oncol 7: 205-207, 1996
10. Kyritsis A, Newlands ES, Brock CS, Gleason M, Jaeckle K, Levin V, Bower M, Evans H, Dane G, Dewitte M, Yung W: Phase II trial of topotecan (T) as a continuous intravenous infusion (CIV) in patients (pts) with high-grade gliomas. Proc Am Soc Clin Oncol 16: 394a (A#1404), 1997
11. Burch PA, Bernath AM, Cascino TL, Scheithauer BW, Novotny P, Nair S, Buckner JC, Pfeifle DM, Kugler JW, Tschetter LK: A North Central Cancer Treatment Group phase II trial of topotecan in relapsed gliomas. Invest New Drugs 18: 275-280, 2000
12. Blaney SM, Cole DE, Balis FM, Godwin K, Poplack DG: Plasma and cerebrospinal fluid pharmacokinetic study of topotecan in nonhuman primates. Cancer Res 53: 725-727, 1993
13. Baker SD, Heideman RL, Crom WR, Kuttesch JF, Gajjar A, Stewart CF: Cerebrospinal fluid pharmacokinetics and penetration of continuous infusion topotecan in children with central nervous systems tumors. Cancer Chemother Pharmacol 37: 195-202, 1996
14. Hochster H, Liebes L, Speyer J, Sorich J, Taubes B, Oratz R, Wernz J, Chachoua A, Raphael B, Vinci RZ et al.: Phase I trial of low-dose continuous topotecan infusion in patients with cancer: An active and well-tolerated regimen. J Clin Oncol 12: 553-559, 1994
15. Houghton PJ, Cheshire PJ, Hallman JD II, Lutz L, Friedman HS, Danks MK, Houghton JA: Efficacy of topoisomerase I inhibitors, topotecan and irinotecan, administered at low dose levels in protracted schedules to mice bearing xenografts of human tumors. Cancer Chemother Pharmacol 36: 393-403, 1995
16. Rowinsky EK, Verweij J: Review of phase I clinical studies with topotecan. Semin Oncol 24: S20-3-S20-10, 1997
17. Arbuck SG, Takimoto CH: An overview of topoisomerase I-targeting agents. Semin Hematol 35: 3-12, 1998
18. Vokes EE, Weichselbaum RR: Concomitant chemoradiotherapy: Rationale and clinical experience in patients with solid tumors. J Clin Oncol 8: 911-934, 1990
19. Honnorat J: Chimioradiothérapie concomitante et tumeurs gliales malignes de l'adulte. Cancer Radiother 2: 672-678, 1998
20. Kim JH, Kim SH, Kolozsvary A, Khil MS: Potentiation of radiation response in human carcinoma cells in vitro and murine fibrosarcoma in vivo by topotecan, an inhibitor of DNA topoisomerase I. Int J Radiat Oncol Biol Phys 22: 515-518, 1992
21. Lamond JP, Mehta MP, Boothman DA: The potential of topoisomerase I inhibitors in the treatment of CNS malignancies: Report of a synergistic effect between topotecan and radiation. J Neuro-Oncol 30: 1-6, 1996
22. Marchesini R, Colombo A, Caserini C, Perego P, Supino R, Capranico G, Tronconi M, Zunino F: Interaction of ionizing radiation with topotecan in two human tumor cell lines. Int J Cancer 66: 342-346, 1996
23. Chastagner P, Kozin SV, Taghian A: Topotecan selectively enhances the radioresponse of human small-cell lung carcinoma and glioblastoma multiforme xenografts in nude mice. Int J Radiat Oncol Biol Phys 50: 777-782, 2001
24. Craig SB, Bhatt UH, Patel K: Stability and compatibility of topotecan hydrochloride for injection with common infusion solutions and containers. J Pharm Biomed Anal 16: 199-205, 1997
25. Faries D: Practical modifications of the continual reassessment method for phase I cancer clinical trials. J Biopharm Stat 4: 147-164, 1994
26. Cairncross G: Topotecan for recurrent malignant glioma: Long times to tumor progression may indicate efficacy. J Neuro-Oncol 30: 163, 1996 (Abstract)
27. Friedman HS, Kerby T, Fields S, Zilisch JE, Graden D, Mclendon RE, Houghton PJ, Arbuck S, Cokgor I, Friedman AH: Topotecan treatment of adults with primary malignant glioma. Cancer 85: 1160-1165, 1999
28. Grabenbauer GG, Buchfelder M, Schrell U, Fahlbusch R, Sauer R, Staab HJ: Topotecan as a 21-day continuous infusion with accelerated 3D-conformal radiation therapy for patients with glioblastoma. Front Radiat Ther Oncol 33: 364-368, 1999
29. Fisher BJ, Scott C, Macdonald DR, Coughlin C, Curran WJ: Phase I study of topotecan plus cranial radiation for glioblastoma multiforme: Results of Radiation Therapy Oncology Group Trial 9507. J Clin Oncol 19: 1111-1117, 2001
30. Bourg V, Lebrum C, Chichmanian RM, Thomas P, Frenay M: Nitroso-urea-cisplatin-based chemotherapy associated with valproate: Increase of haematologic toxicity. Ann Oncol 12: 217-219, 2001
31. Zamboni WC, Gajjar AJ, Heideman RL, Beijnen JH, Rosing H, Houghton PJ, Stewart CF: Phenytoin alters the disposition of topotecan and N-desmethyl topotecan in a patient with medulloblastoma. Clin Cancer Res 4: 783-789, 1998
32. Friedman HS, Petros WP, Frieman AH, Schaaf LJ, Kerby T, Lawyer J, Parry M, Houghton PJ, Lovell S, Rasheed K, Cloughsey T, Stewart ES, Colvin OM, Provenzale JM, McLendon RE, Bigner DD, Cokgor I, Haglund M, Rich J, Ashley D, Malczyn J, Elfring GL, Miller LL: Irinotecan therapy in adults with recurrent or progressive malignant glioma. J Clin Oncol 17: 1516-1525, 1999
33. Creemers GJ, Gerrits CJ, Schellens JH, Planting AS, Van Der Burg ME, Van Beurden VM, De Boer-Dennert M, Harteveld M, Loos W, Hudson I, Stoter G, Verweij J: Phase II and pharmacologic study of topotecan administered as a 21-day continuous infusion to patients with colorectal cancer. J Clin Oncol 14: 2540-2545, 1996
34. Herben VM, Ten Bokkel Huinink WW, Schot ME, Hudson I, Biejnen JH: Continuous infusion of low-dose topotecan: Pharmacokinetics and pharmacodynamics during a phase II study in patients with small cell lung cancer. Anticancer Drugs 9: 411-418, 1998
35. Dainiak N, Kreczko S, Hanspal M, Strauss PR: DNA topoisomerase inhibitors block erythropoiesis and delay hemoglobinization in vitro. J Cell Physiol 138: 87-96, 1989
36. Simpson JR, Horton J, Scott C, Curran WJ, Rubin P, Fischbach J, Isaacson S, Rotman M, Asbell SO, Nelson JS et al.: Influence of location and extent of surgical resection on survival of patients with glioblastoma multiforme: Results of three consecutive Radiation Therapy Oncology Group (RTOG) clinical trials. Int J Radiat Oncol Biol Phys 26: 239-244, 1993
37. Yung WK, Albright RE, Olson J, Fredericks R, Fink K, Prados MD, Brada M, Spence A, Hohl RJ, Shapiro W, Glantz M, Greenberg H, Selker RG, Vick NA, Rampling R, Friedman H, Phillips P, Bruner J, Yue N, Osoba D, Zaknoen S, Levin VA: A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse. Br J Cancer 83: 588-593, 2000